Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Monika Alcobev
Quarter-by-quarter operating performance
Financials of Monika Alcobev
Annual income statement trend
| Mar 2022 3m | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 18 | 140 | 189 | 236 | 301 |
| Expenses + | 15 | 114 | 156 | 190 | 256 |
| Operating Profit | 4 | 26 | 33 | 46 | 45 |
| OPM % | 20% | 18% | 17% | 20% | 15% |
| Other Income + | 0 | 1 | 2 | 4 | 9 |
| Interest | 1 | 6 | 11 | 18 | 18 |
| Depreciation | 0 | 1 | 1 | 1 | 2 |
| Profit before tax | 3 | 19 | 23 | 31 | 35 |
| Tax % | 33% | 31% | 27% | 25% | 7% |
| Net Profit + | 2 | 13 | 17 | 23 | 32 |
| EPS in Rs | 8.90 | 65.15 | 72.62 | 13.87 | 14.98 |
| Dividend Payout % | 0% | 15% | 14% | 10% | 0% |
Financials of Monika Alcobev
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 17 | 21 |
| Reserves | 2 | 15 | 56 | 79 | 223 |
| Borrowings + | 70 | 72 | 123 | 174 | 211 |
| Other Liabilities + | 16 | 39 | 35 | 54 | 37 |
| Total Liabilities | 90 | 129 | 216 | 324 | 492 |
| Fixed Assets + | 6 | 5 | 5 | 19 | 18 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 84 | 123 | 211 | 305 | 474 |
| Total Assets | 90 | 129 | 216 | 324 | 492 |
Financials of Monika Alcobev
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 5 | -6 | -54 | -26 | -102 |
| Cash from Investing Activity + | -0 | 1 | -13 | -26 | -17 |
| Cash from Financing Activity + | 3 | -3 | 67 | 52 | 136 |
| Net Cash Flow | 8 | -8 | 0 | 0 | 17 |
| Free Cash Flow | 4 | -7 | -55 | -39 | -102 |
| CFO/OP | 148% | 0% | -144% | -40% | -214% |
Financials of Monika Alcobev
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 815 | 188 | 185 | 157 | 193 |
| Inventory Days | 897 | 169 | 266 | 374 | 395 |
| Days Payable | 318 | 101 | 43 | 60 | 19 |
| Cash Conversion Cycle | 1,394 | 257 | 408 | 471 | 568 |
| Working Capital Days | 523 | 109 | 102 | 107 | 197 |
| ROCE % | 31% | 25% | 21% | 14% |
For the NSU (Nutraceuticals and Specialty Units) segment, the planned capex for the current year is modest, approximately INR 5-20 crores, focusing on…
Supreme Court's allowance for OMCs to procure 1.49 billion liters for Q4 FY25-'26 could add incremental volume (~4.5 crore liters) for the company in next 2-3…
Chemicals business shows 25% YoY revenue growth; pipeline strong in performance chemicals. Key concall takeaways from India Glycols Ltd's Q1 FY27 earnings call…
Q1 volume growth was 17%; excluding Andhra Pradesh and Delhi, growth was around 13-14%. Key concall takeaways from Allied Blenders's Q1 FY26 earnings call…